• +1-646-491-9876
    • +91-20-67278686

    Search

    Myocardial Fibrosis-Pipeline Review H1 2017

    Myocardial Fibrosis-Pipeline Review H1 2017

    • Report Code ID: RW0001834394
    • Category Pharmaceuticals
    • No. of Pages 68
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Myocardial Fibrosis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Pipeline Review, H1 2017, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

    Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular) .
    - The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Myocardial Fibrosis - Overview
    Myocardial Fibrosis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Myocardial Fibrosis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Myocardial Fibrosis - Companies Involved in Therapeutics Development
    Daewoong Pharmaceutical Co Ltd
    Evotec AG
    Galectin Therapeutics Inc
    GTx Inc
    Invivosciences Inc
    Lead Discovery Center GmbH
    MandalMed Inc
    Merck & Co Inc
    miRagen Therapeutics Inc
    TRACON Pharmaceuticals Inc
    Myocardial Fibrosis - Drug Profiles
    carotuximab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs for Tissue Fibrosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DWN-10290 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GMCT-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GRMD-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GTx-878 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MRG-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NM-922 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SP-20102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TPI-2049 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TRC-205 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Myocardial Fibrosis - Dormant Projects
    Myocardial Fibrosis - Product Development Milestones
    Featured News & Press Releases
    Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Myocardial Fibrosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Myocardial Fibrosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Myocardial Fibrosis - Pipeline by Evotec AG, H1 2017
    Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2017
    Myocardial Fibrosis - Pipeline by GTx Inc, H1 2017
    Myocardial Fibrosis - Pipeline by Invivosciences Inc, H1 2017
    Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, H1 2017
    Myocardial Fibrosis - Pipeline by MandalMed Inc, H1 2017
    Myocardial Fibrosis - Pipeline by Merck & Co Inc, H1 2017
    Myocardial Fibrosis - Pipeline by miRagen Therapeutics Inc, H1 2017
    Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
    Myocardial Fibrosis - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Myocardial Fibrosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Daewoong Pharmaceutical Co Ltd
    Evotec AG
    Galectin Therapeutics Inc
    GTx Inc
    Invivosciences Inc
    Lead Discovery Center GmbH
    MandalMed Inc
    Merck & Co Inc
    miRagen Therapeutics Inc
    TRACON Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//myocardial-fibrosis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//myocardial-fibrosis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//myocardial-fibrosis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments